SUPRIYA — Supriya Lifescience Share Price
Last trade - 00:00- IN₹33.04bn
- IN₹31.90bn
- IN₹4.61bn
- 94
- 12
- 99
- 82
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 20.17 | ||
| PEG Ratio (f) | 0.74 | ||
| EPS Growth (f) | 37.22% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.39 | ||
| Price to Tang. Book | 4.39 | ||
| Price to Free Cashflow | 455.63 | ||
| Price to Sales | 5.96 | ||
| EV to EBITDA | 18.46 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 20.31% | ||
| Return on Equity | 17.14% | ||
| Operating Margin | 28.47% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 2,778.4 | 3,116.44 | 3,853.66 | 5,300.49 | 4,609.38 | 5,689.5 | 7,090.5 | 16.7% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +334.12 | +93.73 | +68.75 | +22.36 | -37.46 | +25.91 | +37.22 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Supriya Lifescience Limited is an India-based manufacturer of active pharmaceutical ingredients (APIs). The Company is primarily engaged in manufacturing of bulk drugs and pharmaceutical chemicals. The Company exports its products in the antihistamine, anesthetics and anti-asthma therapy categories to approximately 86 countries. The Company's product portfolio consists of approximately 38 niche API products that address remedies in therapeutic segments, such as antihistamine, analgesic, vitamin, anesthetics and anti-asthmatics, among others. The Company has manufacturing facilities located in Maharashtra. Its products include Chlorphenamine Maleate, Pheniramine Maleate, Brompheniramine Maleate, Dexchlorpheniramine Maleate, Mepyramine / Pyrilamine Maleate, Dexbrompheniramine Maleate, Cetirizine DiHCL, Diphenhydramine HCL, Bisoprolol Fumarate, Nicorandil, Mecobalamin, Hydroxocobalamin Sulphate, Hydroxocobalamin Acetate, and Hydroxocobalamin Hydrochloride, among others.
Directors
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 26th, 2008
- Public Since
- December 28th, 2021
- No. of Shareholders
- 97,247
- No. of Employees
- 392
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 80,482,800
- Address
- Sonawala Road Goregoan, MUMBAI, 400 063
- Web
- https://supriyalifescience.com/
- Phone
- +91 2240332727
- Contact
- Shweta Singh
- Auditors
- Kakaria & Associates
Similar to SUPRIYA
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
As of Today at 13:21 UTC, shares in Supriya Lifescience are trading at IN₹410.55. This share price information is delayed by 15 minutes.
Shares in Supriya Lifescience last closed at IN₹410.55 and the price had moved by +87.94% over the past 365 days. In terms of relative price strength the Supriya Lifescience share price has outperformed the S&P BSE 100 Index by +46.01% over the past year.
The overall consensus recommendation for Supriya Lifescience is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
The Supriya Lifescience dividend yield is 0.15% based on the trailing twelve month period.
Last year, Supriya Lifescience paid a total dividend of IN₹0.60, and it currently has a trailing dividend yield of 0.15%. We do not have any data on when Supriya Lifescience is to next pay dividends.
We do not have data on when Supriya Lifescience is to next pay dividends. The historic dividend yield on Supriya Lifescience shares is currently 0.15%.
To buy shares in Supriya Lifescience you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹410.55, shares in Supriya Lifescience had a market capitalisation of IN₹33.04bn.
Here are the trading details for Supriya Lifescience:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: SUPRIYA
Based on an overall assessment of its quality, value and momentum Supriya Lifescience is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Supriya Lifescience is IN₹414.50. That is 0.96% above the last closing price of IN₹410.55.
Analysts covering Supriya Lifescience currently have a consensus Earnings Per Share (EPS) forecast of IN₹14.83 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Supriya Lifescience. Over the past six months, its share price has outperformed the S&P BSE 100 Index by +39.1%.
As of the last closing price of IN₹410.55, shares in Supriya Lifescience were trading +37.04% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Supriya Lifescience PE ratio based on its reported earnings over the past 12 months is 20.17. The shares last closed at IN₹410.55.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Supriya Lifescience's directors